Insulin lispro: Its role in the treatment of diabetes mellitus

Annals of Pharmacotherapy

Volumn 30, Issue 11, 1996, Pages 1263-1271

  Campbell, R Keith ^a   Campbell, Lance K ^b   White, John R ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN ALLERGY; INSULIN BLOOD LEVEL; INSULIN PUMP; LIPODYSTROPHY; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029913517     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001111     Document Type: Review

References (50)

1. Cowie CC, Eberhardt MS, eds. Diabetes 1996 vital statistics. Alexandria, VA: American Diabetes Association, 1996:1.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. White JR, Campbell RK. Diabetes. In: Herfindal ET, Gourley DR, Hart LL, eds. Clinical Pharmacy and Therapeutics. 5th ed. Baltimore: Williams and Wilkins, 1992:307-32.
4. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. Lispro human insulin - a rapidly absorbed analog of human insulin. Diabetes 1994; 43:396-402.
5. Galloway JA, Chance RE. Approaches to insulin analogues. In: Marshall SM, Home PD, eds. The diabetes annual/8. New York: Elsevier Science, 1994:277-97.
6. Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges. Horm Metab Res 1994;26:591-8.
7. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 1992;8:259-86.
8. Insulin lispro. Clin Pharmacol Ther 1995;57:98.
9. Betz JL. Fast acting human insulin analogs: a promising innovation in diabetes care. The Diabetes Educ 1995;21:195-200.
10. Insulin lispro. Data on file IV: 1. Indianapolis: Lilly Research Laboratories, 1995.
11. Lougheed WD, Zinman B, Strack TR, Frank BH. Chemical stability of insulin lispro in infusion systems. Diabetes 1996;45(suppl 1):198A.
12. Slieker LJ, Brooke GS, Chance RE, Hoffmann JA, Howey DC, Long HB, et al. Insulin and IGF-I analogs: novel approaches to improved insulin pharmacokinetics. In: LeRoith D, Raizada MK, eds. Current directions in insulin-like growth factor research. New York: Plenum Press, 1994:25-32.
13. Stram LE. The role of the pharmaceutical industry in implementing the DCCT recommendations. Int Diabetes Fed Bull 1994;39(suppl 1):16-20.
14. Ciszak E, Beals JM, Frank BH, Baker JC, Carter ND, Smith JD. Role of c-terminal B-chain residues in insulin assembly: the structure of hexameric lyspro-human insulin. Structure 1995;3:615-22.
15. Woodworth JR, Bowsher RR, Howey DC, Rowe HM, Ferguson AL. Pharmacokinetic (pk) and pharmacodynamic (pd) comparisons of lyspro to Humulin R. Pharm Res 1992;9(suppl):S292.
16. Woodworth J, Howey D, Bowsher R, Lutz S, Santa P, Brady P. Lyspro human insulin (k): dose-ranging vs. Humulin R (H). Diabetes 1993;42 (suppl 1):54A.
17. Howey DC, Hooper SA, Bowsher RR. LysPro human insulin: an equipotent analog of human insulin with rapid onset and short duration of action. Diabetes 1991;40(suppl 1):423A.
18. Vignati L, Anderson JH, Szwast S, Symanowski S. Twice daily lispro results in less glucose variability compared to regular human insulin. Diabetologia 1995;38(suppl 1):A191.
19. Woodworth J, Howey D, Lutz S, Santa P, Brady P, Bowsher R. LysPro human insulin: dose-ranging versus Humulin R. Diabetologia 1993;36 (suppl 1):A155.
20. Jacobs MA, Salobir, Poss-Snijders C, Heine RJ. Hormonal and symptomatic responses to stepwise glucose lowering during LysPro human insulin analog infusion in healthy men. 15th International Diabetes Federation Congress, Kobe, Japan, November 6-11, 1994:256.
21. ter Braak EW, Bianchi R, Erkelens DW. Faster, shorter and more profound action of LysPro human insulin analogue compared to regular insulin irrespective of the injection site. Diabetes 1993;42(suppl 1):207A.
22. Insulin lispro. Data on file IV: 1. Indianapolis: Lilly Research Laboratories, 1996.
23. Crowley M, Alexander W, Cassar DJ, Hitman G, James JM, Kesson CM, et al. Insulin lispro improves postprandial blood glucose control in type 1 and type 2 diabetes without increasing the frequency of hypoglycemia. Diabet Med 1995;12(suppl 2):S33.
24. Pampanelli S, Lepore M, Torlone E, Bartocci L, Lalli C, Brunetti P, et al. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995;18:1452-9.
25. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, et al. LysPro human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995;58:459-69.
26. Vignati L, Anderson JH, Brunelle RL, Jefferson FL, Richardson M. Improvement of glycemic control with the rapidly absorbed lispro insulin analog in type 1 diabetes. Diabetologia 1994;37(suppl 1):A78.
27. Anderson JH, Vignati L, Brunelle RL, Boggs B. Therapy of type 2 diabetes with insulin lispro, a rapidly absorbed insulin analog. Diabetologia 1994;37(suppl 1):A169.
28. Torlone E, Fanelli C, Rambotti AM, Modarelli F, DiVincenzo A, Epifano L, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue LysPro in IDDM. Diabetologia 1994;37:713-20.
29. Garg SK, Carmain JA, Braddy KC, Jennings MK, Chase HP. Pre-meal insulin analog (LysPro) vs. human regular insulin treatment in young subjects with type 1 diabetes. Diabetes 1994;43(suppl 1):162A.
30. Bergenstal R, Spencer M, Castle G, Roethke C, Keough J, Lau A, et al. Intensive insulin management of type I and type II diabetes: a comparison of LysPro and regular human insulin. Diabetes 1994;43(suppl 1): 157A.
31. Brunelle RL, Anderson JH, Vignati L. Decreased rate of hypoglycemia in association with improved metabolic control with insulin lispro. Diabetologia 1994;37(suppl 1):A78.
32. Brunelle RL, Symanowski S, Anderson JH, Vignati L. Less nocturnal hypoglycemia with insulin lispro in comparison to human regular. Diabetes 1995;45(suppl 1):111A.
33. Antsiferov M, Woodworth JR, Mayorov A, Ristic S, Dedov I. Lower within patient variability in postprandial glucose excursion with lispro insulin analog compared to regular insulin. Diabetes 1995;45(suppl 1): 214A.
34. Anderson JH, Brunelle RL, Vignati L. Insulin lispro compared to regular insulin in a crossover study involving 1037 patients with type 1 diabetes. Diabetes 1995;45(suppl 1):228A.
35. Vignati L, Brunelle RL. Treatment of 722 patients with type II diabetes with insulin lispro in a 6 month crossover study. Diabetes 1995;44(suppl 1):229A.
36. Kotsanos JG, Vignati L, Huster W, Andrejasich CM, Galloway JA, Anderson JH. Quality of life in patients with type I diabetes treated with a rapid-acting insulin analog vs. regular insulin: results from a multinational clinical trial. 15th International Diabetes Federation Congress, Kobe, Japan, November 6-11, 1994:124.
37. Letiexhe MR, Rutters A, Schmitt H. LysPro human insulin: patients treated with LysPro vs human regular insulin: quality of life assessment. Diabetologia 1994;37(suppl 1):A168.
38. Desmet M, Rutters A, Schmit H, Satter E. LysPro human insulin (LysPro): patients treated with LysPro vs human regular insulin - quality of life assessment (QOL). Diabetes 1994;43(suppl 1):167A.
39. Trautmann ME. Effect of the insulin analogue LysPro on blood glucose control. Horm Metab Res 1994;12:588-90.
40. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AAR, et al. Pizza, coke and tirami-su: can type 1 diabetic patients cover such a meal with the rapid acting insulin analogue lyspro? Diabetologia 1994;37(suppl 1):302.
41. Symanowski SM, Brunelle RL, Anderson JH. A new technique of population subgroup analysis to evaluate the safety of insulin lispro. 15th International Diabetes Federation Congress, Kobe. Japan, November 6-11, 1994:120.
42. Anderson JH, Symanowski S, Brunelle R. Safety of LysPro human insulin analog in long-term clinical trials. Diabetes 1994;43(suppl 1):61A.
43. Zimmerman J. Subchronic and chronic toxicity, and mutagenicity studies conducted with LysPro human insulin analog, LY275585. 15th International Diabetes Federation Congress, Kobe, Japan, November 6-11, 1994:123.
44. Buelke-Sam J, Byrd RA, Hoyt JA, Zimmerman JL. A reproductive and developmental toxicity study in CD rats of LY275585, (LysPro)-human insulin. J Am Coll Toxicol 1994;13:247-60.
45. Duchateau J, Schreyen H, Dorchy H. Lack of in vitro complement activation by the human insulin analogue LysPro. Diabet Metab 1994;20: 562-3.
46. Fineberg SE, Fineberg NS, Anderson JH, Birkett M. Does the use of short acting LysPro human insulin in insulin naïve patients augment the insulin immune response or differ between type 1 and type 2 patients? Diabetes 1995;44(suppl 1):231A.
47. Fineberg SE, Fineberg NS, Anderson JH, Birkett M, Gibson RG, Hufferd S. Comparative immunogenicity of LysPro (B28,29) human insulin analog between type 1 and type 2 patients. Diabetologia 1994;37(suppl 1):A168.
48. Fineberg NS, Fineberg SE, Anderson JH, Birkett M, Gibson RG, Hufferd S. Does LysPro (B28,29) human insulin analog have altered immunogenicity in patients with type I diabetes? Diabetologia 1994;37 (suppl 1):A167.
49. Lahtela JT, Salmi J, Antonen J, Knip M, Paul R. Severe human insulin antibody-mediated resistance treated with the insulin analogue lispro. Diabetes 1995;44(suppl 1):158A.
50. Henrichs HR, Ungeer H, Fittkau T, Trautmann ME. Treatment of a case of severe subcutaneous insulin resistance using the insulin analogue LysPro for facilitated subcutaneous absorption. Diabetologia 1994;37 (suppl 1):A168.